53.40
-1.16
(-2.13%)
Jun 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
| Range | 53.30 - 54.67 |
| 52 week | 35.50 - 55.94 |
| Open | 54.45 |
| Vol / Avg. | 541,789.00/1.09M |
| Mkt cap | 141,322.35M |
| P/E | 25.52 |
| Div/yield | 1.79/3.36 |
| EPS | 2.09 |
| Shares | 2,646.49M |
| Beta | 0.90 |
| Inst. own | 8% |
Events
Aug 1, 2013
Q2 2013 Sanofi SA Earnings Release
May 3, 2013
Sanofi SA Annual General Meeting
| More events from DailyFinance » |
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 12.66% | 13.19% |
| Operating margin | 18.19% | 17.54% |
| EBITD margin | - | 34.55% |
| Return on average assets | - | 4.72% |
| Return on average equity | - | 8.75% |
| Employees | 111,974 | - |
| Carbon Disclosure Rating | - | 93/100 |
Address
54 rue la Boetie
PARIS, 75008
France
+33-1-53774000 (Phone)
+33-1-53774463 (Fax)
PARIS, 75008
France
+33-1-53774000 (Phone)
+33-1-53774463 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company based in France. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. The Company focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. The Company has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. The Company is active domestically and abroad, including other European countries, North and Latin Americas, Asia, Africa and Middle East. In December 2012, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. In April 2013, the Company inaugurated its logistics platform in Casablanca, Morocco.
Officers and directors
| Serge Weinberg | Chairman of the Board | |
| Christopher A. Viehbacher | Chief Executive Officer, Chairman of the Executive Committee and Global Leadership Team and Director | |
| Jerome Contamine | Executive Vice President - Chief Financial Officer, Member of the Executive Committee and Global Leadership Team | |
| David P. Meeker M.D. | Executive Vice President and Chief Executive Officer of Genzyme, Member of the Global Leadership Team | |
| Gary J. Nabel M.D., Ph.D. | Senior Vice President, Chief Scientific Officer and Deputy to the President for Global R&D, Member of the Global Leadership Team | |
| Karen Linehan | Member of the Executive Board, Member of the Management Board, Senior Vice President, General Counsel | |
| Roberto Pucci | Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | |
| Olivier Charmeil | Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | |
| Philippe Luscan | Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | |
| Jose Barella | Senior Vice President - Animal Health and Member of the Global Leadership Team |